Brokerages predict that Danaher Co. (NYSE:DHR) will report earnings of $1.15 per share for the current quarter, according to Zacks. Eight analysts have made estimates for Danaher’s earnings, with the highest EPS estimate coming in at $1.17 and the lowest estimate coming in at $1.14. Danaher posted earnings of $1.05 per share during the same quarter last year, which would suggest a positive year over year growth rate of 9.5%. The firm is expected to announce its next earnings results before the market opens on Tuesday, January 30th.

According to Zacks, analysts expect that Danaher will report full-year earnings of $3.99 per share for the current fiscal year, with EPS estimates ranging from $3.97 to $4.01. For the next fiscal year, analysts expect that the business will report earnings of $4.32 per share, with EPS estimates ranging from $4.30 to $4.36. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Danaher.

Danaher (NYSE:DHR) last posted its earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, topping the consensus estimate of $0.95 by $0.05. The company had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.87 earnings per share.

Several research firms have recently commented on DHR. Robert W. Baird reissued a “buy” rating on shares of Danaher in a research report on Friday, January 12th. Cowen reissued a “buy” rating and set a $90.00 target price on shares of Danaher in a research report on Wednesday, October 4th. Zacks Investment Research downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Evercore ISI began coverage on shares of Danaher in a research report on Wednesday, January 3rd. They set an “outperform” rating for the company. Finally, Royal Bank of Canada reissued a “hold” rating and set a $96.00 target price on shares of Danaher in a research report on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Danaher presently has an average rating of “Buy” and a consensus target price of $94.91.

Danaher (NYSE DHR) traded up $0.12 during trading hours on Thursday, hitting $99.59. 2,542,800 shares of the stock traded hands, compared to its average volume of 2,493,373. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $69,280.00, a P/E ratio of 29.64, a PEG ratio of 2.16 and a beta of 1.03. Danaher has a one year low of $78.97 and a one year high of $100.27.

The company also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a dividend of $0.14 per share. This represents a $0.56 annualized dividend and a yield of 0.56%. The ex-dividend date is Thursday, December 28th. Danaher’s dividend payout ratio (DPR) is presently 16.67%.

In other Danaher news, CAO Robert S. Lutz sold 11,189 shares of the business’s stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $91.66, for a total value of $1,025,583.74. Following the transaction, the chief accounting officer now directly owns 18,314 shares in the company, valued at $1,678,661.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 273,810 shares of company stock worth $25,218,813. 12.20% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Point72 Asset Management L.P. boosted its stake in Danaher by 276.8% in the third quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock valued at $225,332,000 after acquiring an additional 1,929,751 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Danaher by 16,410.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock valued at $125,395,000 after acquiring an additional 1,476,901 shares during the last quarter. Findlay Park Partners LLP boosted its stake in Danaher by 52.9% in the third quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock valued at $353,186,000 after acquiring an additional 1,425,000 shares during the last quarter. Koch Industries Inc. boosted its stake in Danaher by 29,127.3% in the second quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock valued at $1,388,000 after acquiring an additional 1,399,859 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Danaher by 86.1% in the third quarter. JPMorgan Chase & Co. now owns 3,011,947 shares of the conglomerate’s stock valued at $256,136,000 after acquiring an additional 1,393,165 shares during the last quarter. Hedge funds and other institutional investors own 76.11% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/01/18/1-15-eps-expected-for-danaher-co-dhr-this-quarter.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Get a free copy of the Zacks research report on Danaher (DHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.